[go: up one dir, main page]

MXPA05013121A - Derivados de indol con efecto de induccion de apoptosis. - Google Patents

Derivados de indol con efecto de induccion de apoptosis.

Info

Publication number
MXPA05013121A
MXPA05013121A MXPA05013121A MXPA05013121A MXPA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A MX PA05013121 A MXPA05013121 A MX PA05013121A
Authority
MX
Mexico
Prior art keywords
indole derivatives
apoptosis
inducing effect
medicaments
inducing
Prior art date
Application number
MXPA05013121A
Other languages
English (en)
Inventor
Eckhard Gunther
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03012868A external-priority patent/EP1484329A1/de
Priority claimed from EP04011598A external-priority patent/EP1595878A1/de
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of MXPA05013121A publication Critical patent/MXPA05013121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a derivados de indol usados como medicamentos para el tratamiento de enfermedades de tumor, de manera particular en el caso de resistencia de medicamentos contra otros ingredientes activos y carcinoma en metastasis.
MXPA05013121A 2003-06-05 2004-05-25 Derivados de indol con efecto de induccion de apoptosis. MXPA05013121A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47627703P 2003-06-05 2003-06-05
EP03012868A EP1484329A1 (de) 2003-06-06 2003-06-06 Indolderivate mit Apoptose induzierender Wirkung
EP04011598A EP1595878A1 (de) 2004-05-15 2004-05-15 Indolderivate mit Apoptose induzierender Wirkung
PCT/EP2004/005593 WO2004108702A1 (de) 2003-06-05 2004-05-25 Indolderivate mit apoptose induzierender wirkung

Publications (1)

Publication Number Publication Date
MXPA05013121A true MXPA05013121A (es) 2006-03-17

Family

ID=43661564

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013121A MXPA05013121A (es) 2003-06-05 2004-05-25 Derivados de indol con efecto de induccion de apoptosis.

Country Status (12)

Country Link
EP (1) EP1641777A1 (es)
JP (1) JP4878285B2 (es)
KR (1) KR101132599B1 (es)
CN (1) CN1816543B (es)
AU (1) AU2004245198B2 (es)
BR (1) BRPI0410998A (es)
CA (1) CA2526663C (es)
MX (1) MXPA05013121A (es)
NZ (1) NZ543853A (es)
RS (1) RS20050901A (es)
RU (1) RU2327696C2 (es)
WO (1) WO2004108702A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
JP5527972B2 (ja) * 2005-11-11 2014-06-25 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用
WO2007062399A2 (en) * 2005-11-23 2007-05-31 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
EP2049520A4 (en) * 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
CA2670778A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
JP5749170B2 (ja) * 2008-10-16 2015-07-15 アレイ バイオファーマ、インコーポレイテッド 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
WO2012017325A2 (en) * 2010-07-19 2012-02-09 Procaps Sa Apparatus and process for encapsulating microparticles with liquid in soft gel capsules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1427416A2 (en) * 2001-09-13 2004-06-16 Synta Pharmaceuticals Corporation 3-glyoxlylamideindoles for treating cancer

Also Published As

Publication number Publication date
RU2006100022A (ru) 2006-05-27
AU2004245198B2 (en) 2009-04-23
RS20050901A (sr) 2007-12-31
AU2004245198A1 (en) 2004-12-16
EP1641777A1 (de) 2006-04-05
CN1816543A (zh) 2006-08-09
CN1816543B (zh) 2011-01-19
RU2327696C2 (ru) 2008-06-27
KR20060034230A (ko) 2006-04-21
NZ543853A (en) 2009-09-25
KR101132599B1 (ko) 2012-06-21
JP4878285B2 (ja) 2012-02-15
CA2526663A1 (en) 2004-12-16
WO2004108702A1 (de) 2004-12-16
BRPI0410998A (pt) 2006-07-04
JP2007523850A (ja) 2007-08-23
CA2526663C (en) 2011-07-19

Similar Documents

Publication Publication Date Title
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MXPA05008478A (es) Heterociclos sustituidos.
NO20064584L (no) Tetrahydropyridoindolderivater
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2007127273A3 (en) Methods and compositions for altering cell function
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
TW200517107A (en) Novel formulation
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
DE502007004579D1 (de) Aryl-substituierte heterozyklen und ihre verwendung
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
DE50310038D1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
MXPA05008902A (es) Soluciones de drogas en mentol.
IL194353A0 (en) Lysobactin amides
TW200728295A (en) Benzochromene derivatives
UA86021C2 (ru) Производные индола с эффектом, который индуцирует апоптоз
WO2005018569A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
IL191690A0 (en) Therapy of malignant neoplasias
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors

Legal Events

Date Code Title Description
FG Grant or registration